291 related articles for article (PubMed ID: 21536132)
1. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Butterfield DA; Barone E; Mancuso C
Pharmacol Res; 2011 Sep; 64(3):180-6. PubMed ID: 21536132
[TBL] [Abstract][Full Text] [Related]
2. Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
Ikewaki K; Ayaori M
Circ J; 2011; 75(6):1326-7. PubMed ID: 21532174
[No Abstract] [Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Singh S; Willig JH; Mugavero MJ; Crane PK; Harrington RD; Knopp RH; Kosel BW; Saag MS; Kitahata MM; Crane HM
Clin Infect Dis; 2011 Feb; 52(3):387-95. PubMed ID: 21189273
[TBL] [Abstract][Full Text] [Related]
5. [Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Saku K; Zhang B; Noda K
Nihon Naika Gakkai Zasshi; 2011 Dec; 100(12):3679-86. PubMed ID: 22338904
[No Abstract] [Full Text] [Related]
6. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
7. Statin, the black box.
Hatem S; Boccara F
Arch Cardiovasc Dis; 2008 Jun; 101(6):377-9. PubMed ID: 18809149
[No Abstract] [Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
9. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Saku K; Zhang B; Noda K;
Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
[TBL] [Abstract][Full Text] [Related]
10. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
11. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Davidson M
Prev Cardiol; 2005; 8(4):244-9. PubMed ID: 16230879
[TBL] [Abstract][Full Text] [Related]
12. Is rosuvastatin really a more efficient therapeutic option than atorvastatin?
Soto J; Fernandez de Bobadilla J
Value Health; 2006; 9(4):276-7; author reply 277-9. PubMed ID: 16903999
[No Abstract] [Full Text] [Related]
13. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
14. [Statins: similarities and differences in the pharmacological, clinical and laboratory aspects].
Motti C; Gnasso A; Cortese C
Ann Ital Med Int; 2000; 15(1):96-102. PubMed ID: 10842898
[TBL] [Abstract][Full Text] [Related]
15. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
[TBL] [Abstract][Full Text] [Related]
16. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
[TBL] [Abstract][Full Text] [Related]
17. Effect of two intensive statin regimens on progression of coronary disease.
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
[TBL] [Abstract][Full Text] [Related]
18. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
19. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ
Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272
[TBL] [Abstract][Full Text] [Related]
20. [Pleiotropic effects of statins].
Mennickent C S; Bravo D M; Calvo M C; Avello L M
Rev Med Chil; 2008 Jun; 136(6):775-82. PubMed ID: 18769836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
